113 - Vaxxinity Takes on Neurodegenerative Diseases with Vaccines - Potential Short Opportunity?
Video Sponsor - http://workinbiotech.com/ In this episode, I go through a company called...
45:36
112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRA
In this episode, I take a look at 6 different biotechs and talk about recent updates in each one....
43:59
111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich
Achieve Life Sciences is developing Cytisinicline for the treatment of smoking cessation. The...
28:19
110 - Kodiac Sciences FALLS on Negative Wet AMD Readout! Buying Opportunity or Falling Knife??
Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal...
33:19
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results
Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma...
33:42
108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD
The NASH space has seen some setbacks in the last couple years, but a few players continue to...
37:28
107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients | Interview with CEO Sujal Shah
CymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis...
35:09
106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!
CRISPR is an exciting space, with a number of companies finally sharing early clinical data in...
42:53
105 - Neurodegenerative Disease Recap! ALXO and LGVN updates plus Breaking Breaking 2021 Top Trades
ALXO announces new HR-MDS data that disappoints! I talk about the comparison to Magrolimab data...
41:29
104 - Biotech Bear Market Offers SIGNIFICANT Opportunity in Oncology - CRIS! Longeveron Rises on ODD
Curis is an oncology company trying to develop an inhibitor of IRAK-4. They have shown positive...
48:17
103 - CD47 Companies FALL on New Data! Biogen Negativity Continues with Looming NCD Decision
Two CD47 targeting companies announced data updates from their clinical programs: Shattuk Labs...
37:22
102 - Arvinas' PIONEERING PROTAC Tech to Enhance Cancer Outcomes | Interview with CEO John Houston
Arvinas' PROTAC technology has led to two exciting molecules that are in the clinic for the...
35:13
101 - MAJOR wet AMD/DR SCS Updates from REGENXBIO and CLSD! FDMT XLRP data arrives
REGENXBIO ($RGNX) presents data using the Clearside Bio ($CLSD) SCS injector to treat wet AMD and...
39:08
100 - Absci Leverages AI to Become the GOOGLE of Drug Discovery! Interview with CEO Sean McClain
Absci is a synthetic biology company focused on developing better, faster paths to new medicines....
26:34
099 - Abbvie Announces MASSIVE Interest in REGENXBIO's RGX-314! Readout coming next week
REGENXBIO and Abbvie announce a collaboration to co-develop RGX-314 for the treatment of wet AMD,...
45:48
098 - CD47 Companies RETURN with Trillium Acquisition! Cassava Sciences DROPS on Accusations
Trillium Therapeutics is acquired by Pfizer for $2.26B! Finally, the small-mid cap biotech...
45:32
097 - Tg Therapeutics Q2-2021 Earnings Update | Interview with Michael Weiss - CEO of $TGTX
Tg Therapeutics is a B-cell focused company that recently provided a Q2-2021 update of their...
40:56
096 - Q2-2021 Biotech Earnings - Commercial-Stage Biotech Suffers!
As Q2-2021 earnings season comes to a close, I decided to do a recap on multiple biotech...
52:58
095 - Smid Cap Biotechs Take on Geographic Atrophy (Dry AMD) with MAJOR Readout This Fall
Geographic Atrophy is a progressive disease that leads to degeneration of the macula of the eye....
48:14
094 - Checkpoint Therapeutics Targets MASSIVE Solid Tumor Market | Interview with CEO James Oliviero
Checkpoint Therapeutics ($CKPT) is an clinical stage oncology company that is focusing on...
30:23
Premium
Plus